Effect of RenaGel, a non-absorbed, calcium- and aluminium-free phosphate binder, on serum phosphorus, calcium, and intact parathyroid hormone in end-stage renal disease patients.

Author: BurkeS K, DillonM A, GarrettB, GoldbergD I, GrayJ R, MarburyT, SlatopolskyE A, WeinbergM, WomboltD

Paper Details 
Original Abstract of the Article :
Control of dietary phosphate absorption in end-stage renal disease patients is essential to prevent the deleterious sequelae of phosphorus retention. Efficacy of currently available calcium- and aluminium-containing phosphate binders is constrained by the side-effects associated with the absorption ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1093/ndt/13.9.2303

データ提供:米国国立医学図書館(NLM)

RenaGel: A New Phosphate Binder for End-Stage Renal Disease

Managing phosphate levels in patients with end-stage renal disease is crucial for preventing complications. However, existing phosphate binders, which often contain calcium and aluminum, can have significant side effects. This study explores the efficacy of RenaGel, a calcium- and aluminum-free phosphate binder, in patients with end-stage renal disease.

The study found that RenaGel effectively controlled serum phosphorus levels without the side effects associated with traditional phosphate binders. The researchers observed a significant reduction in serum phosphorus levels in patients treated with RenaGel.

RenaGel: A Safer and More Effective Approach

This study provides strong evidence for the efficacy and safety of RenaGel as a phosphate binder for patients with end-stage renal disease. RenaGel offers a promising alternative to traditional binders, potentially improving patient outcomes and reducing the risk of complications associated with calcium and aluminum absorption.

Dr. Camel's Conclusion

This research offers a beacon of hope for patients with end-stage renal disease. RenaGel offers a safe and effective alternative to traditional phosphate binders, potentially improving patient outcomes and reducing the risk of complications. It's a testament to the ongoing quest for better treatment options in the ever-evolving field of medicine.

Date :
  1. Date Completed 1998-12-23
  2. Date Revised 2019-05-12
Further Info :

Pubmed ID

9761513

DOI: Digital Object Identifier

10.1093/ndt/13.9.2303

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.